JP2009533323A - Hsp90阻害剤として用いられるピロロピリミジン誘導体 - Google Patents

Hsp90阻害剤として用いられるピロロピリミジン誘導体 Download PDF

Info

Publication number
JP2009533323A
JP2009533323A JP2008558881A JP2008558881A JP2009533323A JP 2009533323 A JP2009533323 A JP 2009533323A JP 2008558881 A JP2008558881 A JP 2008558881A JP 2008558881 A JP2008558881 A JP 2008558881A JP 2009533323 A JP2009533323 A JP 2009533323A
Authority
JP
Japan
Prior art keywords
pyrrolo
pyrimidine
phenyl
alk
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008558881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533323A5 (enExample
Inventor
ブロウ,ポール,アンドリュー
ドライスデール,マーティン,ジェームズ
デイビス,ニコラス,ガレス,モース
フォロップ,ニコラス,ノエル
ストークス,ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0604944.9A external-priority patent/GB0604944D0/en
Priority claimed from GBGB0617789.3A external-priority patent/GB0617789D0/en
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2009533323A publication Critical patent/JP2009533323A/ja
Publication of JP2009533323A5 publication Critical patent/JP2009533323A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2008558881A 2006-03-11 2007-03-09 Hsp90阻害剤として用いられるピロロピリミジン誘導体 Withdrawn JP2009533323A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0604944.9A GB0604944D0 (en) 2006-03-11 2006-03-11 Pyrrolopyrimidine compounds
GBGB0617789.3A GB0617789D0 (en) 2006-09-09 2006-09-09 Pyrrolopyrimidine compounds
PCT/GB2007/000831 WO2007104944A1 (en) 2006-03-11 2007-03-09 Pyrrolopyrimidine derivatives used as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
JP2009533323A true JP2009533323A (ja) 2009-09-17
JP2009533323A5 JP2009533323A5 (enExample) 2010-04-30

Family

ID=38038718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558881A Withdrawn JP2009533323A (ja) 2006-03-11 2007-03-09 Hsp90阻害剤として用いられるピロロピリミジン誘導体

Country Status (11)

Country Link
US (1) US20090163490A1 (enExample)
EP (1) EP2007767B1 (enExample)
JP (1) JP2009533323A (enExample)
KR (1) KR20090007319A (enExample)
AT (1) ATE531718T1 (enExample)
AU (1) AU2007226344A1 (enExample)
BR (1) BRPI0708779A2 (enExample)
CA (1) CA2645343A1 (enExample)
EA (1) EA200801968A1 (enExample)
MX (1) MX2008011559A (enExample)
WO (1) WO2007104944A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521489A (ja) * 2014-06-13 2017-08-03 ユマ セラピューティクス,インコーポレーテッド ピリミジン化合物およびその使用方法
JP2020510668A (ja) * 2016-11-18 2020-04-09 システィック ファイブロシス ファンデーション セラピューティクス インコーポレイテッドCystic Fibrosis Foundation Therapeutics Inc. Cftr増強物質としてのピロロピリミジン

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030871A1 (en) * 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
GB0718433D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
JP5690823B2 (ja) 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN103298817A (zh) 2011-01-07 2013-09-11 利奥制药有限公司 作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドPlexxikon Inc. キナーゼをモジュレートするための化合物および方法、ならびにその指標
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3194975A4 (en) 2014-09-17 2018-05-02 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DE60236458D1 (de) * 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017521489A (ja) * 2014-06-13 2017-08-03 ユマ セラピューティクス,インコーポレーテッド ピリミジン化合物およびその使用方法
US10336768B2 (en) 2014-06-13 2019-07-02 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
US10961254B2 (en) 2014-06-13 2021-03-30 Yuma Therapeutics, Inc. Pyrimidine compounds and methods using the same
JP2020510668A (ja) * 2016-11-18 2020-04-09 システィック ファイブロシス ファンデーション セラピューティクス インコーポレイテッドCystic Fibrosis Foundation Therapeutics Inc. Cftr増強物質としてのピロロピリミジン

Also Published As

Publication number Publication date
CA2645343A1 (en) 2007-09-20
ATE531718T1 (de) 2011-11-15
MX2008011559A (es) 2008-11-25
BRPI0708779A2 (pt) 2011-06-14
EP2007767B1 (en) 2011-11-02
EP2007767A1 (en) 2008-12-31
EA200801968A1 (ru) 2009-02-27
US20090163490A1 (en) 2009-06-25
KR20090007319A (ko) 2009-01-16
WO2007104944A1 (en) 2007-09-20
AU2007226344A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
EP1675861B1 (en) Pyrimidothiophene compounds
EP2007767B1 (en) Pyrrolopyrimidine derivatives used as hsp90 inhibitors
US7803831B2 (en) 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer
CN100455586C (zh) 嘧啶并噻吩化合物
US20090181989A1 (en) Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer
JP4891904B2 (ja) ピリミドチオフェン化合物
US20110034457A1 (en) Pyridothiophene Compounds
US20100010037A1 (en) 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors
CN101432287A (zh) 用作hsp90抑制剂的吡咯并嘧啶衍生物
WO2006090094A1 (en) Pyrimidothiophene compounds for use as hsp90 inhibitors
EP1851228B1 (en) Pyrimidothiophene compounds having hsp90 inhibitory activity
HK1095591B (en) Pyrimidothiophene compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100309

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111104